Dashboard
Portfolios
Watchlist
Community
Discover
Screener
Narratives
Loading...
Community
/
United States
/
Pharmaceuticals & Biotech
/
10x Genomics
Create a narrative
10x Genomics Community
NasdaqGS:TXG Community
3
Narratives
written by author
0
Comments
on narratives written by author
23
Fair Values set
on narratives written by author
Community Investing Ideas
10x Genomics
Popular
Undervalued
Overvalued
10x Genomics
AN
AnalystConsensusTarget
Consensus Narrative from 14 Analysts
Advanced Genomics Tools Will Shape Future Precision Medicine
Key Takeaways Expansion of product offerings and strategic acquisitions are enhancing innovation, reducing operational costs, and solidifying leadership in advanced genomics tools. Growth in global partnerships and improved international presence are increasing market opportunities and supporting resilient, long-term revenue streams.
View narrative
US$15.08
FV
13.5% undervalued
intrinsic discount
2.22%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
16
users have followed this narrative
18 days ago
author updated this narrative
10x Genomics
AN
AnalystHighTarget
Consensus Narrative from 14 Analysts
Advanced Genomics Trends Will Unlock Precision Medicine
Key Takeaways Accelerating adoption of innovative products and new data-driven applications is driving faster-than-expected revenue growth and expanding high-margin software and consumables streams. Expansion in biopharma, global research, and new regulatory-backed markets are enabling rapid, diversified growth and improved long-term earnings stability.
View narrative
US$18
FV
27.6% undervalued
intrinsic discount
7.88%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
1
users have followed this narrative
about 1 month ago
author updated this narrative
10x Genomics
AN
AnalystLowTarget
Consensus Narrative from 14 Analysts
US Funding Cuts And Global Pressures Will Hamper Progress
Key Takeaways Uncertain government and academic funding, plus shifting policy priorities, threaten core revenue growth and long-term market potential. Competitive pressure, high costs, and regulatory risks may erode margins and market share, limiting profitability and earnings recovery.
View narrative
US$9
FV
44.9% overvalued
intrinsic discount
0.88%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
0
users have followed this narrative
about 2 months ago
author updated this narrative